Meatly’s latest £10.4 million Series A is more than a financing milestone; it is a deliberate bet that cultivated meat can graduate from promising science to industrial reality. Backed by new European venture funds and returning supporters, the London startup is using the capital to build a 20,000-litre bioreactor facility that it says will be Europe’s largest cultivated meat plant. The company’s near-term commercial target is pet food, a lower-friction market that lets it prove scale, cost discipline and operational reliability while regulation remains tighter for human food. For investors, the message is clear: Meatly is pursuing infrastructure first, market expansion second.

Funding Signals Confidence

Meatly’s raise lands at a moment when cultivated meat still divides opinion, but the size and quality of the round suggest serious institutional conviction. The company said investor demand exceeded its original target, a sign that its technical progress and commercialization roadmap resonated with backers looking beyond the hype cycle. The financing lifts Meatly’s total funding to £17.4 million, including the £7 million seed round that helped bring the business to this point.

The Series A was led by three new European venture capital firms: Oyster Bay Venture Capital, Clean Growth Fund and JamJar Investments. Their participation matters because it broadens Meatly’s cap table beyond the early believers and gives the company deeper access to foodtech, climate-tech and consumer-sector networks.

Why Meatly Matters

Founded in 2022 by Owen Ensor and Dr. Helder Cruz, Meatly makes real chicken meat from animal cells without slaughter, placing it among the earliest European companies to move cultivated meat beyond the laboratory and into early commercialization. In 2024, it became the first company in Europe to receive regulatory approval for cultivated meat, then followed that with the launch of a cultivated pet food product.

That sequence is important. Meatly is not trying to force cultivated meat directly into the toughest market first. Instead, it is building a commercial beachhead in pet food, where regulatory hurdles are lower and the use case is easier to explain to consumers. That is a classic start-up strategy: find the narrowest viable lane, establish proof of demand and economics, then widen the road later.

Building At Scale

The headline use of the new money is a 20,000-litre bioreactor facility in London, which Meatly says will be the largest cultivated meat production site in Europe. Fit-out is expected to begin immediately, with first output targeted for 2027.
This is not just a capacity play. It is also a signal about where Meatly believes the industry’s bottleneck really sits. Cultivated meat has often been discussed in terms of biology, ethics and regulation, but the commercial hurdle is manufacturing: how to produce consistently, at volume, and at a cost that can survive contact with the market. Meatly is making the case that the answer lies in owning the production stack rather than relying on a patchwork of outside suppliers.

Backers And Strategy

Oyster Bay Venture Capital, based in Hamburg, framed its investment around sustainability, ethics and Meatly’s ability to move from concept to practical deployment. Clean Growth Fund focused on climate impact and cost competitiveness, arguing that changing how protein is produced is central to tackling emissions. JamJar Investments, the London consumer fund backed by the founders of Innocent Drinks, brings a brand-building and consumer-market perspective to the round.
Returning investors also reinforced the round’s credibility. Agronomics, the AIM-listed clean food investor and founding backer, said Meatly has consistently focused on reducing the cost of production through in-house bioreactors and its own culture medium. Following the financing, Agronomics said its stake would be carried at £3.2 million, representing 11.57% ownership on a fully diluted basis.
Pets at Home also returned to the table, reflecting the strategic fit between Meatly’s pet food focus and a major UK retail channel already positioned near the end customer. That kind of alignment is valuable in an emerging category where distribution can matter as much as technology.

Cost Curve Improvements

What likely persuaded investors most was not the concept alone, but the company’s record of pushing down costs fast. In 2024, Meatly developed a protein-free culture medium with no serum or animal-derived components, priced at just £1 per litre, far below the hundreds of pounds typically associated with incumbent inputs. It later cut that to 22p per litre and said the figure could fall to 1.5p at industrial scale.
The company has also taken an unusually hands-on approach to equipment. It built a custom pilot-scale bioreactor with a capacity of 320 litres for about £12,500, which it said is roughly 95% cheaper than traditional fermenters that can cost as much as £250,000.
That kind of cost compression is exactly what makes a tough category investable: not because the business is solved, but because it is demonstrably moving in the right direction.

A simplified view of the operating leap looks like this:

Pet Food As Entry Point

Meatly’s near-term commercial logic is rooted in pragmatism. The new facility is expected to support continuous production of cultivated chicken for the UK pet food market, with product releases from the site likely in 2027.
That choice is shrewd. Pet food offers a clearer path to market than human food, where consumer acceptance, labeling scrutiny and regulatory timelines can become expensive and slow. It also creates a commercial proving ground where Meatly can test throughput, unit economics and supply-chain stability without needing to convince a mass human-food audience on day one. In that sense, pet food is less a detour than a strategic on-ramp.

For investors, the logic is familiar: prove the plant, prove the process, prove the margins, then decide whether the platform can expand into larger markets. The market opportunity is far bigger if cultivated chicken eventually reaches human consumption, but credibility has to be earned one production cycle at a time.

Sector Context

The round arrives against a mixed backdrop for alternative protein. Capital has been harder to raise across the sector, and many start-ups have faced pressure to move from visionary messaging to hard evidence of manufacturability and demand. At the same time, the regulatory picture has improved, with seven cultivated meat products cleared for sale across multiple countries over the past 12 months.
That combination matters. Regulation alone does not build a business, but it does reduce existential uncertainty. Meatly’s raise suggests that some investors still see selective opportunities in cultivated meat, especially where the company has a credible path to production infrastructure and a realistic commercial entry point. The emphasis now is less on whether the category can exist and more on which operators can survive the capital intensity required to bring it to scale.

Investor Takeaway

Meatly is making a calculated infrastructure-first move: spend now on production capability, use pet food to establish operating evidence, and build the manufacturing credibility needed for a broader future. The approach may not deliver quick consumer-brand glamour, but it addresses the central weakness that has dogged much of cultivated meat: the gap between scientific promise and industrial economics.

For investors watching the space, the key question is not whether cultivated meat is interesting. It is whether any company can reduce costs fast enough, secure enough regulatory clarity, and build enough operational scale to become more than a niche story. Meatly is now one of the clearest tests of that proposition in Europe.